Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.
Standard
Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. / Mikesch, Jan-Henrik; Buerger, Horst; Simon, Ronald; Brandt, Burkhard.
In: BBA-BIOMEMBRANES, Vol. 1766, No. 1, 1, 2006, p. 42-52.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.
AU - Mikesch, Jan-Henrik
AU - Buerger, Horst
AU - Simon, Ronald
AU - Brandt, Burkhard
PY - 2006
Y1 - 2006
N2 - The decay-accelerating factor (DAF, CD55) physiologically serves as an inhibitor of the complement system. Moreover, DAF is broadly expressed in malignant tumors. Here, DAF seems to dispose of several different functions reaching far beyond its immunological role, e.g., promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathway activation, and specific seven-span transmembrane receptors (CD97) binding. Furthermore, DAF has already been included in diagnostic or therapeutic studies. Thereby, studies applying monoclonal anti-DAF antibodies and anti-DAF vaccination for a targeted therapy have been enrolled recently.
AB - The decay-accelerating factor (DAF, CD55) physiologically serves as an inhibitor of the complement system. Moreover, DAF is broadly expressed in malignant tumors. Here, DAF seems to dispose of several different functions reaching far beyond its immunological role, e.g., promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathway activation, and specific seven-span transmembrane receptors (CD97) binding. Furthermore, DAF has already been included in diagnostic or therapeutic studies. Thereby, studies applying monoclonal anti-DAF antibodies and anti-DAF vaccination for a targeted therapy have been enrolled recently.
M3 - SCORING: Zeitschriftenaufsatz
VL - 1766
SP - 42
EP - 52
JO - BBA-BIOMEMBRANES
JF - BBA-BIOMEMBRANES
SN - 0005-2736
IS - 1
M1 - 1
ER -